GDRX: Pharma Direct And Pharmacy Partnerships Will Drive Future Upside

Analysts have cut their average price targets for GoodRx to a range of about $2 to $3.50, citing a take rate reset that pressures near term growth and margins in the core Prescription Transaction business, while pointing to Pharma Direct as a key source of potential upside.

Analyst Commentary

Recent Street research on GoodRx reflects a wide reset in expectations, with lower price targets across the board and mixed views on the company’s ability to execute through the take rate reset and business shift toward Pharma Direct and branded drugs.

Bullish Takeaways

Bullish analysts highlight that, even with lower targets in the US$2 to US$3.50 range, valuations already factor in pressure on the core Prescription Transaction business. They see this as creating room for upside if execution on Pharma Direct goes well.
Some bullish analysts maintain positive ratings after the reset, pointing to the Pharma Direct unit as a source of potential growth that could diversify revenues away from the more pressured prescription discount model.
Where analysts reference recent quarterly results, they note that revenue and EBITDA came in ahead of their expectations. This supports the view that the current reset is more about future economics with partners than current operational capability.
Bullish analysts view the company’s focus on branded drugs and Pharma Direct as a way to reposition the business model. If executed well, this could help justify their higher end of the new target range.

Bearish Takeaways

Bearish analysts focus on the “unexpected” take rate reset, calling out structural headwinds in Prescription Transaction that are pressuring growth and margins and, in their view, warranting lower valuation multiples.
Several firms now sit at Neutral or Hold, reflecting caution that the shift toward Pharma Direct will take time to show through, while the core Prescription Transaction business faces reduced economics with partners and competitive pricing pressure.
JPMorgan describes the outlook as “murky,” citing lighter-than-expected 2026 guidance and an estimate that Prescription Transaction could be down 14% year over year in 2026, which they see as a risk to execution on the transition story.
Some bearish analysts point to investor concern around longer dated guidance and evolving partner terms. Combined with reduced price targets down to as low as US$2, this signals limited confidence that near term execution will support higher valuations.

What's in the News

GoodRx technology is being used to power the TrumpRx website, according to reporting that links the platform to President Trump’s initiative around prescription access (STAT periodical).
GoodRx launched Employer Direct, a program that lets employers subsidize discounted cash prices on high cost brand drugs, including GLP-1 weight loss treatments such as Wegovy, without changing core health plan design (Key Developments).
GoodRx entered Lilly’s Employer Connect network, giving self insured employers access to Zepbound KwikPen at a set US$449 price across all doses through GoodRx Employer Direct, with the option to add employer subsidies at the pharmacy counter (Key Developments).
Surescripts introduced Script Corner, a patient price transparency tool that includes discounted cash prices through an exclusive partnership with GoodRx, integrating GoodRx pricing directly into a prescription management app for participating health systems (Key Developments).
GoodRx expanded RxSmartSaver at Giant Eagle pharmacies, allowing customers to scan a QR code at the counter to access manufacturer copay cards and nearly 80 discounted cash prices on high cost brand medications, including GLP-1 drugs such as Ozempic and Wegovy (Key Developments).

Valuation Changes

Fair Value: cut from about $4.56 to $2.82, a reduction of roughly 38% in the modeled estimate.
Discount Rate: raised slightly from 9.83% to 10.40%, implying a higher required return in the updated assumptions.
Revenue Growth: lowered from 5.52% to 2.84%, reflecting a more conservative outlook on future dollar sales expansion.
Net Profit Margin: reduced from 10.33% to 5.83%, indicating a smaller share of dollar revenue assumed to flow through to net income.
Future P/E: increased from 18.1x to 22.6x, suggesting a higher earnings multiple applied to the updated earnings stream.

4 views

Key Takeaways

Expanding uninsured populations and rising drug prices are increasing demand for GoodRx's affordable prescription solutions and growing its user base.
New pharma partnerships, digital health integrations, and targeted subscription services are boosting higher-margin, recurring, and diversified revenue streams.
Reliance on third-party partners, regulatory shifts, new competitors, and evolving pharmacy models threaten GoodRx's revenue stability, user growth, pricing power, and market position.

Catalysts

About GoodRx Holdings

Offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.What are the underlying business or industry changes driving this perspective?

Increased uninsured and underinsured populations due to recent cuts in Medicaid funding and rising health premiums are likely to drive more Americans to seek affordable prescription solutions, boosting GoodRx's addressable market and supporting growth in transaction revenues.
Accelerating adoption of digital health and telemedicine, along with heightened consumer price sensitivity in the face of drug price inflation, positions GoodRx's platform as an increasingly vital resource, expanding its user base and raising potential for recurring revenue through digital pharmacy integrations.
Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.
Launch and planned expansion of condition-specific and pharmacy subscription offerings (e.g., ED, weight loss, hair loss) utilize GoodRx's large, engaged audience, increasing customer lifetime value and generating more predictable and diversified revenue streams.
Deeper integration with pharmacies (pharmacy counter initiatives, e-commerce, Community Link for independents) improves partnership durability and operational efficiency, leading to higher retention, reduced churn from external disruptions, and better margin stability over time.

GoodRx Holdings Earnings and Revenue Growth

GoodRx Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming GoodRx Holdings's revenue will grow by 2.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.8% today to 5.8% in 3 years time.
Analysts expect earnings to reach $50.5 million (and earnings per share of $0.2) by about March 2029, up from $30.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $78.5 million in earnings, and the most bearish expecting $18.1 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.7x on those 2029 earnings, down from 22.8x today. This future PE is lower than the current PE for the US Healthcare Services industry at 32.8x.
Analysts expect the number of shares outstanding to decline by 4.09% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.4%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Structural changes in the pharmacy and PBM ecosystem, such as the Rite Aid bankruptcy and rapid network removals, have led to immediate and significant volume shocks for GoodRx, exposing its reliance on third-party partners and indicating ongoing risks to top-line revenue whenever major partners experience operational distress or make network changes.
Erosion in the Integrated Savings Program (ISP), particularly due to PBM partners restructuring or deprioritizing the program, demonstrates how GoodRx's ability to drive prescription transaction volumes is increasingly subject to decisions outside its control; this can result in direct revenue loss, increased choppiness in monthly active user counts, and future gross margin compression.
The pivot toward cost-plus and more bespoke pharmacy arrangements, while intended to improve retail partner economics, has led to higher prices at the point of sale, pressuring consumer demand for cash-pay scripts, which could further accelerate the shift of scripts back to funded benefits and constrain growth in GoodRx's core user base-ultimately impacting both revenue and net margins.
Intensifying competition in direct-to-consumer prescription models (e.g., Amazon Pharmacy, digital-first health platforms) and the prospect of vertical integration among PBMs, health plans, and retail pharmacies pose a disintermediation threat to GoodRx, as competitors may bypass or undercut its pricing tools, shrinking market share and reducing future top line expansion.
Regulatory changes increasing healthcare price transparency or implementing government-driven direct-to-consumer pricing models (e.g., Most Favored Nation pricing proposals) may "commoditize" GoodRx's offerings, eroding their pricing power and reducing their differentiation, which could shrink the addressable market and exert sustained pressure on revenues and margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $2.82 for GoodRx Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.5, and the most bearish reporting a price target of just $1.9.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $866.6 million, earnings will come to $50.5 million, and it would be trading on a PE ratio of 22.7x, assuming you use a discount rate of 10.4%.
Given the current share price of $2.03, the analyst price target of $2.82 is 27.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on GoodRx Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digital Health And Telemedicine Expansion Will Deepen Market Opportunity